KROS: Keros Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-07-29 | 13G amendment | BlackRock, Inc. | 8.40% | SEC |
Institutional ownership (Q2 2026)
132 institutions reported holding $210.28M of Keros Therapeutics, Inc. on Form 13F (151 the quarter before). 14 opened a new position and 30 sold out. Shares held by institutions: +7%.
| Largest holders | Shares | Value |
|---|---|---|
| Nantahala Capital Management, LLC | 2,820,838 | $30.18M |
| BlackRock, Inc. | 2,794,217 | $29.90M |
| AQR CAPITAL MANAGEMENT LLC | 967,859 | $10.36M |
| VANGUARD CAPITAL MANAGEMENT LLC | 833,596 | $8.92M |
| ORBIMED ADVISORS LLC | 759,155 | $8.12M |
| FEDERATED HERMES, INC. | 700,427 | $7.49M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 652,635 | $6.98M |
| MACKENZIE FINANCIAL CORP | 628,438 | $6.72M |
| Madison Avenue Partners, LP | 626,583 | $6.70M |
| Qube Research & Technologies Ltd | 608,837 | $6.51M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.